SH2B3 and acute lymphoblastic leukemia: Kinase activating gene alterations were noted in 91% of patients with Ph-like B-ALL and included ABL fusions (ABL1, ABL2, CSF1R, PDGFRB) in 12%, EPOR rearrangement in 4%, JAK2 rearrangement in 7%, CRLF2 rearrangement in 50%, other JAK/STAT alterations (IL7R, FLT3, SH2B3, JAK1, JAK3, TYK2, IL2RB) in 12%, RAS mutations in 4%, and uncommon fusions (NTRK3 or DGKH) in 1%.